441 related articles for article (PubMed ID: 30504327)
21. Increased mTORC2 pathway activation in lymph nodes of iMCD-TAFRO.
Phillips AD; Kakkis JJ; Tsao PY; Pierson SK; Fajgenbaum DC
J Cell Mol Med; 2022 Jun; 26(11):3147-3152. PubMed ID: 35488725
[TBL] [Abstract][Full Text] [Related]
22. Immune-mediated thrombocytopenia and IL-6-mediated thrombocytosis observed in idiopathic multicentric Castleman disease.
Rubenstein AI; Pierson SK; Shyamsundar S; Bustamante MS; Gonzalez MV; Milller ID; Brandstadter JD; Mumau MD; Fajgenbaum DC
Br J Haematol; 2024 Mar; 204(3):921-930. PubMed ID: 38168727
[TBL] [Abstract][Full Text] [Related]
23. Idiopathic multicentric Castleman disease (iMCD)-idiopathic plasmacytic lymphadenopathy: A distinct subtype of iMCD-not otherwise specified with different clinical features and better survival.
Gao YH; Liu YT; Zhang MY; Li SY; Fajgenbaum DC; Zhang L; Li J
Br J Haematol; 2024 May; 204(5):1830-1837. PubMed ID: 38356434
[TBL] [Abstract][Full Text] [Related]
24. Bone marrow findings of idiopathic Multicentric Castleman disease: A histopathologic analysis and systematic literature review.
Belyaeva E; Rubenstein A; Pierson SK; Dalldorf D; Frank D; Lim MS; Fajgenbaum DC
Hematol Oncol; 2022 Apr; 40(2):191-201. PubMed ID: 35104370
[TBL] [Abstract][Full Text] [Related]
25. Elevated serum interferon γ-induced protein 10 kDa is associated with TAFRO syndrome.
Iwaki N; Gion Y; Kondo E; Kawano M; Masunari T; Moro H; Nikkuni K; Takai K; Hagihara M; Hashimoto Y; Yokota K; Okamoto M; Nakao S; Yoshino T; Sato Y
Sci Rep; 2017 Feb; 7():42316. PubMed ID: 28205564
[TBL] [Abstract][Full Text] [Related]
26. Clinical and pathological characteristics of HIV- and HHV-8-negative Castleman disease.
Yu L; Tu M; Cortes J; Xu-Monette ZY; Miranda RN; Zhang J; Orlowski RZ; Neelapu S; Boddu PC; Akosile MA; Uldrick TS; Yarchoan R; Medeiros LJ; Li Y; Fajgenbaum DC; Young KH
Blood; 2017 Mar; 129(12):1658-1668. PubMed ID: 28100459
[TBL] [Abstract][Full Text] [Related]
27. The clinicopathological comparison among nodal cases of idiopathic multicentric Castleman disease with and without TAFRO syndrome.
Kurose N; Futatsuya C; Mizutani KI; Kumagai M; Shioya A; Guo X; Aikawa A; Nakada S; Fujimoto S; Kawabata H; Masaki Y; Takai K; Aoki S; Kojima M; Nakamura S; Yamada S
Hum Pathol; 2018 Jul; 77():130-138. PubMed ID: 29684500
[TBL] [Abstract][Full Text] [Related]
28. T-Cells Subsets in Castleman Disease: Analysis of 28 Cases Including Unicentric, Multicentric and HHV8-Related Clinical Forms.
Fraticelli S; Lucioni M; Neri G; Marchiori D; Cristinelli C; Merli M; Monaco R; Borra T; Lazzaro A; Uccella S; Arcaini L; Paulli M
Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175521
[TBL] [Abstract][Full Text] [Related]
29. Treatment consistent with idiopathic multicentric Castleman disease guidelines is associated with improved outcomes.
Pierson SK; Lim MS; Srkalovic G; Brandstadter JD; Sarmiento Bustamante M; Shyamsundar S; Mango N; Lavery C; Austin B; Alapat D; Lechowicz MJ; Bagg A; Li H; Casper C; van Rhee F; Fajgenbaum DC
Blood Adv; 2023 Nov; 7(21):6652-6664. PubMed ID: 37656441
[TBL] [Abstract][Full Text] [Related]
30. HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapy.
Fajgenbaum DC; van Rhee F; Nabel CS
Blood; 2014 May; 123(19):2924-33. PubMed ID: 24622327
[TBL] [Abstract][Full Text] [Related]
31. From Castleman disease histopathological features to idiopathic multicentric Castleman disease: a multiparametric approach to exclude potential iMCD histopathological mimickers.
Rodriguez Merino L; Pomares AA; Arce JR; Montes-Moreno S
J Clin Pathol; 2024 Apr; 77(5):318-323. PubMed ID: 36690434
[TBL] [Abstract][Full Text] [Related]
32. Characteristics of thrombocytopenia, anasarca, fever, reticulin fibrosis and organomegaly syndrome: a retrospective study from a large Western cohort.
Maisonobe L; Bertinchamp R; Damian L; Gérard L; Berisha M; Guillet S; Fieschi C; Malphettes M; Fadlallah J; Hié M; Dunogué B; De Wilde V; Vandergheynst F; Zafrani L; Grall M; Saada N; Garzaro M; Oksenhendler E; Galicier L; Boutboul D
Br J Haematol; 2022 Feb; 196(3):599-605. PubMed ID: 34585382
[TBL] [Abstract][Full Text] [Related]
33. A benefit and the prospects of IL-6 inhibitors in idiopathic multicentric Castleman's disease.
Koga T; Sumiyoshi R; Kawakami A; Yoshizaki K
Mod Rheumatol; 2019 Mar; 29(2):302-305. PubMed ID: 30285516
[TBL] [Abstract][Full Text] [Related]
34. Long-Term Tolerance and Efficacy of Siltuximab (Anti-IL-6) in a Young Adult with Idiopathic Multicentric Castleman Disease During COVID-19.
Bedier H; Isnard S; Maedler-Kron C; Routy JP
Eur J Case Rep Intern Med; 2023; 10(12):004098. PubMed ID: 38077710
[TBL] [Abstract][Full Text] [Related]
35. Siltuximab: a targeted therapy for idiopathic multicentric Castleman disease.
Fajgenbaum DC; Kurzrock R
Immunotherapy; 2016; 8(1):17-26. PubMed ID: 26634298
[TBL] [Abstract][Full Text] [Related]
36. TAFRO Syndrome.
Igawa T; Sato Y
Hematol Oncol Clin North Am; 2018 Feb; 32(1):107-118. PubMed ID: 29157612
[TBL] [Abstract][Full Text] [Related]
37. Next-generation sequencing of idiopathic multicentric and unicentric Castleman disease and follicular dendritic cell sarcomas.
Nagy A; Bhaduri A; Shahmarvand N; Shahryari J; Zehnder JL; Warnke RA; Mughal T; Ali S; Ohgami RS
Blood Adv; 2018 Mar; 2(5):481-491. PubMed ID: 29496669
[TBL] [Abstract][Full Text] [Related]
38. International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease.
van Rhee F; Oksenhendler E; Srkalovic G; Voorhees P; Lim M; Dispenzieri A; Ide M; Parente S; Schey S; Streetly M; Wong R; Wu D; Maillard I; Brandstadter J; Munshi N; Bowne W; Elenitoba-Johnson KS; Fössa A; Lechowicz MJ; Chandrakasan S; Pierson SK; Greenway A; Nasta S; Yoshizaki K; Kurzrock R; Uldrick TS; Casper C; Chadburn A; Fajgenbaum DC
Blood Adv; 2020 Dec; 4(23):6039-6050. PubMed ID: 33284946
[TBL] [Abstract][Full Text] [Related]
39. Utility of renal biopsy in differentiating idiopathic multicentric Castleman disease from IgG4-related disease.
Kawanishi M; Kamei F; Sonoda H; Oba M; Fukunaga S; Egawa M; Koyama T; Sato Y; Tanabe K; Ito T
CEN Case Rep; 2023 May; 12(2):242-248. PubMed ID: 36414812
[TBL] [Abstract][Full Text] [Related]
40. Idiopathic Plasmacytic Lymphadenopathy Forms an Independent Subtype of Idiopathic Multicentric Castleman Disease.
Nishikori A; Nishimura MF; Nishimura Y; Otsuka F; Maehama K; Ohsawa K; Momose S; Nakamura N; Sato Y
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142213
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]